Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + trastuzumab in HER2-overexpressing EGFR-mutated NSCLC after TKI progression
NL-OMON44719Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and trastuzumab in non-small cell lung cancer (NSCLC), sponsored by Vrije University Medical Center. Primary endpoint: Objective response rate. Started May 2015; status: active, not recruiting.
02
Drugs
paclitaxeltrastuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44719.